Education
About Us
Working with TipRanks
Follow Us
Laboratorios Farmaceuticos Rovi, SA (ES:ROVI)
BME:ROVI
RESEARCH TOOLSreports
Total Valuation
Laboratorios Farmaceuticos Rovi has a market cap or net worth of €2.59B. The enterprise value is €3.32B.
Market Cap€2.59B
Enterprise Value€3.32B
Share Statistics
Laboratorios Farmaceuticos Rovi has 51,235,764 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,235,764
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Laboratorios Farmaceuticos Rovi’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is 19.78%.
Return on Equity (ROE)0.24
Return on Assets (ROA)0.16
Return on Invested Capital (ROIC)19.78%
Return on Capital Employed (ROCE)0.27
Revenue Per Employee347.63K
Profits Per Employee80.88K
Employee Count2,197
Asset Turnover0.92
Inventory Turnover0.86
Valuation Ratios
The current PE Ratio of Laboratorios Farmaceuticos Rovi is 23.58. Laboratorios Farmaceuticos Rovi’s PEG ratio is -1.25.
PE Ratio23.58
PS Ratio0.02
PB Ratio5.64
Price to Fair Value5.64
Price to FCF42.43
Price to Operating Cash Flow23.34
PEG Ratio-1.25
Income Statement
In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of 763.75M and earned 136.88M in profits. Earnings per share was 2.67.
Revenue763.75M
Gross Profit478.35M
Operating Income179.54M
Pretax Income177.69M
Net Income136.88M
EBITDA207.69M
Earnings Per Share (EPS)2.67
Cash Flow
In the last 12 months, operating cash flow was 138.28M and capital expenditures -62.22M, giving a free cash flow of 76.06M billion.
Operating Cash Flow138.28M
Free Cash Flow76.06M
Free Cash Flow per Share1.48
Dividends & Yields
Laboratorios Farmaceuticos Rovi pays an annual dividend of €0.893, resulting in a dividend yield of 1.75%
Dividend Per Share€0.893
Dividend Yield1.75%
Payout Ratio30.07%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change-37.50%
50-Day Moving Average52.04
200-Day Moving Average66.21
Relative Strength Index (RSI)52.44
Average Volume (3m)126.55K
Important Dates
Laboratorios Farmaceuticos Rovi upcoming earnings date is May 7, 2025, TBA Not Confirmed.
Last Earnings DateFeb 25, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend DateJul 08, 2024
Financial Position
Laboratorios Farmaceuticos Rovi as a current ratio of 3.13, with Debt / Equity ratio of 20.00%
Current Ratio3.13
Quick Ratio1.02
Debt to Market Cap0.03
Net Debt to EBITDA0.42
Interest Coverage Ratio90.31
Taxes
In the past 12 months, Laboratorios Farmaceuticos Rovi has paid 40.81M in taxes.
Income Tax40.81M
Effective Tax Rate0.23
Enterprise Valuation
Laboratorios Farmaceuticos Rovi EV to EBITDA ratio is 15.96, with an EV/FCF ratio of 43.58.
EV to Sales4.34
EV to EBITDA15.96
EV to Free Cash Flow43.58
EV to Operating Cash Flow23.97
Balance Sheet
Laboratorios Farmaceuticos Rovi has €27.41M in cash and marketable securities with €114.41M in debt, giving a net cash position of €87.00M billion.
Cash & Marketable Securities€27.41M
Total Debt€114.41M
Net Cash€87.00M
Net Cash Per Share€1.70
Tangible Book Value Per Share€10.68
Margins
Gross margin is 64.23%, with operating margin of 23.51%, and net profit margin of 17.92%.
Gross Margin64.23%
Operating Margin23.51%
Pretax Margin23.27%
Net Profit Margin17.92%
EBITDA Margin27.19%
EBIT Margin23.53%
Analyst Forecast
The average price target for Laboratorios Farmaceuticos Rovi is €77.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€77.75
Price Target Upside52.00% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―